Yu, E. Y., Pieczonka, C. M., Armstrong, A. J., Suzuki, H., Bailen, J. L., Murphy, D. G., … Briganti, A. (2022). DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40, pp. E17029–E17029).

Yu, Evan Y., Christopher Michael Pieczonka, Andrew J. Armstrong, Hiroyoshi Suzuki, James L. Bailen, Declan G. Murphy, Thierry Lebret, et al. “DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC).” In JOURNAL OF CLINICAL ONCOLOGY, 40:E17029–E17029, 2022.

Yu EY, Pieczonka CM, Armstrong AJ, Suzuki H, Bailen JL, Murphy DG, et al. DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). In: JOURNAL OF CLINICAL ONCOLOGY. 2022. p. E17029–E17029.

Yu, Evan Y., et al. “DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC).” JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 16, 2022, pp. E17029–E17029.

Yu EY, Pieczonka CM, Armstrong AJ, Suzuki H, Bailen JL, Murphy DG, Lebret T, Luz M, Thiery-Vuillemin A, Ortiz JA, Khan J, Briganti A. DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). JOURNAL OF CLINICAL ONCOLOGY. 2022. p. E17029–E17029.